Sixth People's Hospital

Shanghai Sixth People's Hospital and Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University were established in 1904 and are a large-scale comprehensive teaching hospital of Grade A. There are 1766 approved beds , 1950 actually opened beds , and 43 clinical medical technical departments. Hospital 2013 emergency door amounted to 337.39 million people, the number of patients discharged 8.60 million passengers, surgery 8.29 million. The hospital has 6 national clinical key specialties (Orthopedics, Endocrinology and Metabolism, Otorhinolaryngology, Radiology, Sports Medicine, Emergency Medicine), and 3 national key disciplines (Orthopedics, Endocrinology and Metabolic Diseases, Cardiovascular Diseases) school), Shanghai "top priority" clinical Center 2 Ge (metabolic diseases, orthopedic trauma), Shanghai "most important" key clinical disciplines 1 Ge (Otolaryngology). The hospital has a national comprehensive hospital model TCM department, Shanghai Acute Trauma Emergency Center, Shanghai Specialized Infectious Disease Diagnosis and Treatment Center, Shanghai Critical Maternity Consultation and Rescue Center, and Shanghai Stroke Clinical Rescue Center. The hospital has Shanghai Medical Equipment Management Quality Control Center and Shanghai Medical Record Quality Management Quality Control Center. The hospital has been awarded the honorary title of "National Civilized Unit" for three consecutive nine years. Over the years, it has been awarded the honorary titles of National Advanced Unit of Health System, National May 1st Labor Certificate, National Advanced Unit of Open and Democratic Management of Factory Affairs, National Advanced Unit of Hospital Management Year. Shanghai Sixth People's Hospital drug clinical trial institution (hereinafter referred to as the "Agency") to build in 2004 Nian 5 months, in 2006 Nian 1 month by the China Food and Drug Administration ( CFDA qualified) certificate drug clinical trial institution, and in 2012 Obtained the CFDA qualification review inspection certificate in February . The institution currently has 13 professional groups in endocrinology , cardiovascular , respiratory , digestive , orthopedics , nephropathy , blood , tumor , infection , anesthesia , general surgery , traditional Chinese encephalopathy , and medical imaging. It has a total of 13 professional groups engaged in clinical trials and development of new drugs within the above-mentioned professional scope. Qualifications and conditions for clinical trials of medical devices and in vitro diagnostic reagents. Under the supervision and guidance of the National Health and Family Planning Commission and CFDA , the institution strictly follows the requirements of the "Quality Management Standards for Drug Clinical Trials", ensuring that drug clinical trial projects can be scientifically regulated, comply with ethics, and safety in terms of personnel, systems, venues, and equipment. To implement. The agency has a drug clinical trial agency office, which is mainly responsible for the unified management, supervision and guidance of professional drug clinical trials. The institution has established a relatively complete clinical trial management system, standard operating procedures ( SOP ) and quality assurance system, and established a special drug clinical trial center pharmacy, equipped with full-time institutional quality administrators , drug administrators, and data administrators. The quality of clinical trials, experimental drugs and data files are managed; the clinical trial-related medical technology departments are equipped with appropriate equipment for testing, inspection and diagnosis related to drug clinical trials. In recent years, the institution has undertaken more than 150 multi-center drug / medical device / in vitro diagnostic reagent clinical trial projects. Each professional group has accumulated rich clinical trial experience and a good working foundation in drug clinical trial research . The projects undertaken successfully passed the inspection by the US Food and Drug Administration ( FDA ), the third-party inspection by the sponsor, and the on-site registration inspection by the provincial drug regulatory authority